Codexis Future Growth
Future criteria checks 1/6
Codexis is forecast to grow earnings and revenue by 45.5% and 19.9% per annum respectively while EPS is expected to grow by 47.7% per annum.
Key information
45.5%
Earnings growth rate
47.7%
EPS growth rate
Life Sciences earnings growth | 17.8% |
Revenue growth rate | 19.9% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
Is Codexis (NASDAQ:CDXS) Using Debt In A Risky Way?
Dec 10Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors
Nov 07After Leaping 26% Codexis, Inc. (NASDAQ:CDXS) Shares Are Not Flying Under The Radar
Jul 26Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?
Jul 12Investors Appear Satisfied With Codexis, Inc.'s (NASDAQ:CDXS) Prospects
May 29Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story
Dec 20What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?
Dec 19Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?
Nov 15Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S
Jun 28Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Jun 07At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?
May 09Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts
Feb 27We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Feb 25Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?
Nov 05Codexis appoints Kevin Norrett as chief operating officer
Oct 03We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth
Aug 23Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%
Jul 28Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead
Jul 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 86 | -36 | -21 | N/A | 4 |
12/31/2025 | 67 | -53 | -35 | N/A | 7 |
12/31/2024 | 65 | -58 | -55 | N/A | 8 |
9/30/2024 | 64 | -62 | -46 | -44 | N/A |
6/30/2024 | 61 | -76 | -49 | -47 | N/A |
3/31/2024 | 74 | -65 | -54 | -51 | N/A |
12/31/2023 | 70 | -76 | -57 | -53 | N/A |
9/30/2023 | 74 | -82 | -41 | -37 | N/A |
6/30/2023 | 99 | -57 | -6 | -1 | N/A |
3/31/2023 | 116 | -48 | 8 | 13 | N/A |
12/31/2022 | 139 | -34 | 3 | 11 | N/A |
9/30/2022 | 133 | -31 | -7 | 7 | N/A |
6/30/2022 | 135 | -19 | -29 | -13 | N/A |
3/31/2022 | 122 | -21 | -35 | -19 | N/A |
12/31/2021 | 105 | -21 | -28 | -14 | N/A |
9/30/2021 | 101 | -15 | -26 | -16 | N/A |
6/30/2021 | 83 | -23 | -26 | -20 | N/A |
3/31/2021 | 72 | -25 | -27 | -21 | N/A |
12/31/2020 | 69 | -24 | -20 | -16 | N/A |
9/30/2020 | 67 | -21 | -21 | -19 | N/A |
6/30/2020 | 70 | -14 | -20 | -16 | N/A |
3/31/2020 | 68 | -14 | -15 | -11 | N/A |
12/31/2019 | 68 | -12 | -16 | -13 | N/A |
9/30/2019 | 66 | -12 | -14 | -10 | N/A |
6/30/2019 | 61 | -14 | -12 | -10 | N/A |
3/31/2019 | 62 | -11 | -16 | -13 | N/A |
12/31/2018 | 61 | -11 | -17 | -14 | N/A |
9/30/2018 | 66 | -9 | -8 | -6 | N/A |
6/30/2018 | 59 | -18 | N/A | -9 | N/A |
3/31/2018 | 56 | -20 | N/A | -9 | N/A |
12/31/2017 | 50 | -23 | N/A | -9 | N/A |
9/30/2017 | 38 | -29 | N/A | -12 | N/A |
6/30/2017 | 43 | -18 | N/A | -14 | N/A |
3/31/2017 | 49 | -9 | N/A | -6 | N/A |
12/31/2016 | 49 | -9 | N/A | -2 | N/A |
9/30/2016 | 50 | -5 | N/A | 0 | N/A |
6/30/2016 | 53 | -1 | N/A | 8 | N/A |
3/31/2016 | 43 | -9 | N/A | 4 | N/A |
12/31/2015 | 42 | -8 | N/A | 0 | N/A |
9/30/2015 | 44 | -5 | N/A | -3 | N/A |
6/30/2015 | 34 | -15 | N/A | -1 | N/A |
3/31/2015 | 35 | -18 | N/A | -1 | N/A |
12/31/2014 | 35 | -19 | N/A | 0 | N/A |
9/30/2014 | 31 | -29 | N/A | -9 | N/A |
6/30/2014 | 27 | -34 | N/A | -19 | N/A |
3/31/2014 | 28 | -38 | N/A | -22 | N/A |
12/31/2013 | 32 | -41 | N/A | -23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDXS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CDXS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CDXS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CDXS's revenue (19.9% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: CDXS's revenue (19.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDXS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 07:54 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Codexis, Inc. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
J. Horwitz | Baird |
Vishal Shah | Barclays |
Robert Wasserman | Benchmark Company |